Generate Biomedicines

Generate Biomedicines is a biotechnology company pioneering a machine learning-driven approach to drug discovery and development. Founded in 2018 by the venture creation firm Flagship Pioneering, the company is headquartered in Cambridge, Massachusetts, within the greater Boston biotech hub. Its core mission is to use generative artificial intelligence to design novel protein therapeutics across a wide range of disease areas, aiming to accelerate and expand the pipeline of biologic medicines.

Company overview

Generate Biomedicines operates as a clinical-stage biotechnology company, distinguishing itself through its foundational integration of artificial intelligence with biological science. The firm emerged from the research incubator Flagship Labs, a unit of Flagship Pioneering known for founding companies like Moderna and Indigo Agriculture. Its operational model combines extensive wet-lab facilities with computational research, employing a multidisciplinary team of scientists in fields like computational biology, protein engineering, and machine learning. The company’s rapid growth has been supported by significant venture capital, positioning it among a new wave of AI in healthcare companies transforming drug development.

Technology and platform

The company’s proprietary platform, termed its generative AI platform, is designed to learn the complex rules governing protein structure and function from vast datasets of known protein sequences and structures. This technology draws inspiration from advances in large language models like GPT-3, applying similar principles to the "language" of amino acids to generate novel protein designs with desired properties. The platform can theoretically create proteins de novo, including complex modalities like monoclonal antibodies, cytokines, and enzyme replacements, without being limited to naturally occurring templates. This approach is intended to overcome traditional challenges in biologics discovery, such as immunogenicity and stability, by computationally optimizing designs before they are synthesized and tested in the laboratory.

Research and development

Generate Biomedicines’ research pipeline spans several therapeutic areas, with initial programs focused on oncology, immunology, and infectious diseases. Its most advanced programs aim to create targeted protein therapeutics for cancers and autoimmune disorders. A notable public demonstration of its platform was the rapid computational design of a novel protein that could bind to a key site on the SARS-CoV-2 spike protein during the COVID-19 pandemic. The company is building a broad portfolio of drug candidates, advancing select molecules through preclinical development toward Investigational New Drug applications with the U.S. Food and Drug Administration. Its R&D strategy emphasizes speed and scale, aiming to generate and screen thousands of potential drug candidates computationally to identify the most promising for experimental validation.

Partnerships and collaborations

To validate and deploy its technology, Generate Biomedicines has entered into strategic partnerships with established pharmaceutical companies. A significant collaboration was formed with Amgen in 2022, a multi-year agreement focusing on the discovery and development of protein therapeutics for five clinical targets across several disease areas. This deal, potentially worth over $1.9 billion, provides Generate with upfront payment, research funding, and milestone payments. The company also collaborates with the United States Department of Defense and research institutions to explore applications of its platform for national security and public health challenges, such as responding to pandemic threats.

Leadership and funding

The company is led by Chief Executive Officer Michael Nally, formerly an executive at Merck & Co., and was co-founded by Flagship Pioneering partners Geoffrey von Maltzahn and Molly Gibson. Its scientific leadership includes experts from institutions like MIT and Harvard University. Generate Biomedicines has secured substantial funding through private investment rounds led by Flagship Pioneering, along with participation from other investors such as Alaska Permanent Fund, Altitude Life Science Ventures, and ARCH Venture Partners. In 2021, the company announced a $370 million Series B financing round, one of the largest private financings in biotechnology that year, to scale its platform and advance its pipeline toward the clinic.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Artificial intelligence companies Category:Flagship Pioneering